Fulgent Genetics, Inc. (FRA:7F0)
Germany · Delayed Price · Currency is EUR 22.60
-0.60 (-2.59%)
At close: Jan 28, 2026
Fulgent Genetics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 315.55 | 283.47 | 289.21 | 618.97 | 992.58 | 421.71 | |
Revenue Growth (YoY) | 13.61% | -1.99% | -53.27% | -37.64% | 135.37% | 1196.46% |
Cost of Revenue | 185.41 | 176.26 | 184.76 | 252.07 | 215.53 | 89.81 |
Gross Profit | 130.14 | 107.22 | 104.46 | 366.9 | 777.05 | 331.91 |
Selling, General & Admin | 141.29 | 124.35 | 130.47 | 149.99 | 75.17 | 30.17 |
Research & Development | 51.85 | 48.82 | 41.44 | 28.91 | 24.22 | 11.58 |
Amortization of Goodwill & Intangibles | 8 | 7.97 | 7.85 | 6.5 | 1.71 | - |
Operating Expenses | 201.14 | 181.13 | 179.75 | 185.4 | 101.1 | 41.75 |
Operating Income | -70.99 | -73.92 | -75.3 | 181.5 | 675.95 | 290.16 |
Interest Expense | -0.06 | - | -0.49 | -1.01 | -0.18 | - |
Interest & Investment Income | 32.11 | 31.3 | 21.61 | 5.62 | 0.34 | 1.44 |
Earnings From Equity Investments | - | - | - | - | - | -0.49 |
Other Non Operating Income (Expenses) | 0.08 | 0.73 | 0.32 | 0.89 | - | - |
EBT Excluding Unusual Items | -38.87 | -41.88 | -53.85 | 187 | 676.11 | 291.11 |
Merger & Restructuring Charges | - | - | - | -2.98 | - | - |
Impairment of Goodwill | - | - | -120.23 | - | - | - |
Gain (Loss) on Sale of Investments | -10.07 | -10.07 | - | - | 4.92 | -4.26 |
Pretax Income | -48.8 | -51.96 | -174.09 | 184.03 | 681.03 | 286.84 |
Income Tax Expense | -4.63 | -8.14 | 1.15 | 42.1 | 174.8 | 72.53 |
Earnings From Continuing Operations | -44.17 | -43.82 | -175.24 | 141.92 | 506.24 | 214.31 |
Net Income to Company | -44.17 | -43.82 | -175.24 | 141.92 | 506.24 | 214.31 |
Minority Interest in Earnings | 1.19 | 1.11 | 7.41 | 1.48 | 1.13 | - |
Net Income | -42.98 | -42.71 | -167.83 | 143.4 | 507.36 | 214.31 |
Net Income to Common | -42.98 | -42.71 | -167.83 | 143.4 | 507.36 | 214.31 |
Net Income Growth | - | - | - | -71.74% | 136.74% | - |
Shares Outstanding (Basic) | 31 | 30 | 30 | 30 | 29 | 23 |
Shares Outstanding (Diluted) | 31 | 30 | 30 | 31 | 31 | 24 |
Shares Change (YoY) | 2.27% | 1.51% | -3.81% | -0.04% | 28.77% | 28.58% |
EPS (Basic) | -1.40 | -1.41 | -5.63 | 4.76 | 17.25 | 9.44 |
EPS (Diluted) | -1.40 | -1.41 | -5.63 | 4.63 | 16.38 | 8.91 |
EPS Growth | - | - | - | -71.73% | 83.84% | - |
Free Cash Flow | -19.85 | -19.26 | 4.8 | 234.75 | 514.77 | 105.5 |
Free Cash Flow Per Share | -0.65 | -0.64 | 0.16 | 7.58 | 16.62 | 4.39 |
Gross Margin | 41.24% | 37.82% | 36.12% | 59.28% | 78.29% | 78.70% |
Operating Margin | -22.50% | -26.08% | -26.03% | 29.32% | 68.10% | 68.81% |
Profit Margin | -13.62% | -15.07% | -58.03% | 23.17% | 51.12% | 50.82% |
Free Cash Flow Margin | -6.29% | -6.79% | 1.66% | 37.92% | 51.86% | 25.02% |
EBITDA | -46.79 | -48.99 | -49.15 | 214.16 | 686.96 | 293.12 |
EBITDA Margin | -14.83% | -17.28% | -16.99% | 34.60% | 69.21% | 69.51% |
D&A For EBITDA | 24.2 | 24.93 | 26.14 | 32.66 | 11 | 2.96 |
EBIT | -70.99 | -73.92 | -75.3 | 181.5 | 675.95 | 290.16 |
EBIT Margin | -22.50% | -26.08% | -26.03% | 29.32% | 68.10% | 68.81% |
Effective Tax Rate | - | - | - | 22.88% | 25.67% | 25.29% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.